Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus FLURBIPROFEN.
Head-to-head clinical analysis: ALEVE D SINUS COLD versus FLURBIPROFEN.
ALEVE-D SINUS & COLD vs FLURBIPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Cyclooxygenase (COX) inhibitor, reducing prostaglandin synthesis; nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
Oral: 50-100 mg every 6-8 hours; maximum 300 mg/day. Ophthalmic: 1 drop every 30 minutes starting 2 hours before surgery, then 1 drop every 4-6 hours for 24-48 hours post-surgery.
None Documented
None Documented
Clinical Note
moderateFlurbiprofen + Gatifloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateFlurbiprofen + Rosoxacin
"Flurbiprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateFlurbiprofen + Levofloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateFlurbiprofen + Trovafloxacin
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Terminal elimination half-life: 3-4 hours (healthy adults) in short-term use; prolonged to 6-12 hours in elderly or renal impairment.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Renal: 70% as conjugated metabolites (e.g., glucuronides) and <5% unchanged; biliary/fecal: 30%, with enterohepatic circulation.
Category C
Category D/X
NSAID/Decongestant Combination
NSAID
"Flurbiprofen may increase the neuroexcitatory activities of Trovafloxacin."